

BIOGRAPHICAL SKETCH

NAME: Wang, Lisa

EDUCATION

INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD
University of Western Ontario	Master	2003	Statistics
Shangdong University of Technology	Bachelor	1991	Engineering

RESEARCH AND PROFESSIONAL EXPERIENCE:

EMPLOYMENT:

2005-Present Biostatistician, Dept. of Biostatistics, Princess Margaret Hospital
2004-2005 Biostatistician, Cancer Informatics, Princess Margaret Hospital
2002-2003 Teaching & Research assistant, Dept. of Statistics, University of Western Ontario
1995-2000 Budget Analyst, Energy center, University of Petroleum, China
1991-1994 Junior Engineer, Maintenance Dept., University of Petroleum, China

HONOURS/AWARDS:

Special University Scholarship, University of Western Ontario 2002-2003
Advanced Member Award, University of Petroleum 1998
University Scholarship, Shangdong University of Technology 1988-1991

PROFESSIONAL COMMITTEES:

Data and Safety Monitoring Board, Ontario Cancer Institute (Princess Margaret Hospital).
Data and Safety Monitoring Board, Drug Development Program, Princess Margaret Hospital

ACADEMIC SOCIETIES:

Society for Clinical Trials

BOOK CHAPTERS:

Khetan, V., Chan, H., Wang, L., Gallie, B.: Prognostic Factors in Cancer, 3E, M. K. Gospodarowicz, Editor, J. Wiley & Sons, Inc., Hoboken, NJ, 39: 273-277, 2006.

GRANTS:

PI Forsyth, Peter, Wang, L. et al: Phase I pharmacodynamic and "high content" study of the gamma-secretase inhibitor RO4929097 in patients with recurrent malignant gliomas (MGs) targeting p75NTR to inhibit brain tumour initiating cells (BTICs) and recurrent invasive gliomas CCSRI (2010-2012) (\$312, 282)

RECENT PUBLICATIONS:

Gynecol Oncol. 2012 Apr;125(1):136-40. doi: 10.1016/j.ygyno.2011.11.042. Epub 2011 Dec 2. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM.

Cancer Chemother Pharmacol. 2012 May;69(5):1339-44. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. Renouf DJ, Welch S, Moore MJ, Krzyzanowska MK, Knox J, Feld R, Liu G, MacKay H, Petronis J, Wang L, Chen E.

Ann Oncol. 2012 Jun;23(6):1562-70. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, Siu LL.

Invest New Drugs. 2012 Jun;30(3):1158-63. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM.

Am J Clin Oncol. 2012 Jun;35(3):255-60. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V, Siu LL.

Invest New Drugs. 2012 Jun;30(3):1203-7. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ.

J Pain Symptom Manage. 2012 Jul;44(1):64-73. A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. Salvador P, Azusano C, Wang L, Howell D.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e167-72. How effective is a virtual consultation process in facilitating multidisciplinary decision-making for malignant epidural spinal cord compression? Fitzpatrick D, Grabarz D, Wang L, Bezjak A, Fehlings MG, Fosker C, Rampersaud R, Wong RK.

Clin Cancer Res. 2012 Nov 1;18(21):6023-31. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ.

A handwritten signature in black ink, appearing to be 'Liz J. M. S.', located at the bottom right of the page.